Work

Responsiveness to Cetuximab without Mutations inEGFR

Year: 2005

Type: article

Abstract: that in contrast to the correlation of mutations with responses to the EGFR kinase inhibitors gefitinib and erlotinib, EGFR mutations are not critical for the response of a tumor to cetuximab.

Source: New England Journal of Medicine

DOI: 10.1056/nejm200507143530218

Authors: Zenta Tsuchihashi, Shirin Khambata-Ford, Nasser Hanna, Pasi A. Jänne

Institutions: Bristol-Myers Squibb (United States), Indiana University Indianapolis, Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1997488475

FWCI: 11.82

Cites: 5

Cited by: 118

Related to: 10